Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway

Cancer Cell International

Xiongpeng Zhu¹  Quanyi Lu²  Xiuli Hong²  Xiao Huang²  Jiasheng Hu¹ 

[1] Department of Haematology, First Hospital of Quanzhou Affiliated Fujian Medical University, Quanzhou, Fujian, 36200, China;Department of Haematology, Zhongshan Hospital of Xiamen University, Xiamen, Fujian 361004, China

关键词: Gene expression;    Notch signal;    Multiple myeloma;    Arsenic trioxide;   

Others  :  794159
DOI  :  10.1186/1475-2867-13-25

 received in 2013-01-07, accepted in 2013-03-07,  发布年份 2013

【 摘 要 】

Arsenic Trioxide (ATO) has shown remarkable efficacy for the treatment of multiple myeloma (MM). However, the mechanism by which ATO exerts its inhibitory effect on the proliferation of myeloma cells remains to be clarified. We study the inhibitory effect of ATO at various concentrations on the proliferation of the myeloma cell line RPMI 8226 and discussed the molecular mechanism of ATO on myeloma cell line. Our results proved that ATO had a significant dose-dependent and time-dependent inhibitory effect on the expressions of the Notch receptor (Notch1) and Notch ligand (Jag2). Data from the real-time PCR assay showed that the mRNA expression levels of the Jag2 gene and its downstream gene Hes1 were both significantly down-regulated after the myeloma cells were treated with ATO while the expression of the tumor suppressor gene PTEN was up-regulated. These results elucidated the molecular mechanism underlying the ATO mediated inhibition of myeloma cell proliferation. This is the first report on the anti-myeloma activity in myeloma cells through inhibition of the Notch signaling pathway.

【 授权许可】

   
2013 Hu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Lenhoff S, Hjorth M, Holmberg E: Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000, 95:7-11.
• [2]Harousseau JL, Moreau P, Attal M, Facon T, Avet LH: Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2005, 18:603-618.
• [3]Kastrinakis NG, Gorgoulis VG, Foukas PG, Dimopoulos MA, Kittas C: Molecular aspects of multiple myeloma. Ann Oncol 2000, 11:1217-1228.
• [4]Schwarzenbach H: Expression of MDR1/Pglycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002, 19:87-104.
• [5]Kyle RA, Rajkumar SV: Multiple Myeloma. New Engl J Med 2004, 351:1860-1873.
• [6]Park WH, Seol JG, Kim ES: Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis. Cancer Res 2000, 60:3065-3071.
• [7]Rousselot P, Larghero J, Labaume S: Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 2004, 72:166-171.
• [8]Campbell RA, Sanchez E, Steinberg JA: Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. Br J Haematol 2007, 138:467-478.
• [9]Kalmadi SR, Hussein MA: The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Acta Haematol 2006, 116:1-7.
• [10]Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007, 13:1762-1768.
• [11]Abou-Jawde RM, Reed J, Kelly M: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 2006, 23:263-272.
• [12]Hayashi T, Hideshima T, Akiyama M: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 2002, 1:851-860.
• [13]Wu X, Shi J, Wu Y: Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther 2010, 10(11):1201-1214.
• [14]Osborne B, Miele L: Notch and the immune system. Immunity 1999, 11:653-663.
• [15]Leong KG, Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood 2006, 107:2223-33.
• [16]Jundt F, Anagnostopoulos I, Forster R: Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002, 99(9):3398-3403.
• [17]Hubmann R, Schwarzmeier JD, Shehata M: Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 2002, 99:3742-3747.
• [18]Tohda S, Nara N: Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. LeuK Lymphoma 2001, 42:467-472.
• [19]Weijzen S, Zlobin A, Braid M: HPV16 E6 and E7 oncoproteins regulate notch-1 expression and cooperate to induce transformation. Cell Physiol 2003, 194:356-362.
• [20]Weng AP, Nam Y, Wolfe MS: Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003, 23(2):655-664.
• [21]Houde C, Li Y, Song L: Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines [J]. Blood 2004, 104:3697-3704.
• [22]Lu Q, Lin X, Feng J: Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008, 1:6-10. BioMed Central Full Text
• [23]Wen J, Cheng HY, Feng Y: P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 2008, 140:169-180.
• [24]Drobna Z, Jaspers I, Thomas DJ, Styblo M: Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 2008, 17:67-69.
• [25]Davison K, Mann KK, Waxman S, Miller WH: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004, 103:3496-3502.
• [26]Palomero T, Dominguez M, Ferrando AA: The role of the PTEN/AKT Pathway in NOTCH1- induced leukemia [J]. Cell Cycle 2008, 7:965-970.
• [27]Palomero T, Sulis ML, Cortina M: Mutational Loss of PTEN induces resistance to Notch1 inhibition in T-cell leukemia [J]. Nat Med 2007, 13:1203-1210.
• [28]Chen G, Wang Y, Huang H: Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol 2009, 82:176-83.
• [29]Lunghi P, Giuliani N, Mazzera L: Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008, 112:2450-62.
• [30]Wen J, Feng Y, Huang W: Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010, 34:85-92.